Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | opioid receptor, mu 1 | Starlite/ChEMBL | References |
Homo sapiens | nitric oxide synthase 1 (neuronal) | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0027 | 1 | 0.5 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0027 | 1 | 1 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0027 | 1 | 1 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0014 | 0.0151 | 0.0151 |
Brugia malayi | FAD binding domain containing protein | 0.0027 | 1 | 1 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0027 | 1 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0027 | 1 | 0.5 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0027 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0027 | 1 | 0.5 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0027 | 1 | 0.5 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0027 | 1 | 1 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0017 | 0.2407 | 0.2407 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0027 | 1 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0013 | 0 | 0.5 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0027 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0027 | 1 | 1 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0027 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0027 | 1 | 1 |
Leishmania major | p450 reductase, putative | 0.0027 | 1 | 1 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0027 | 1 | 1 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0027 | 1 | 1 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0027 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.0024 | 0.7743 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0013 | 0 | 0.5 |
Chlamydia trachomatis | sulfite reductase | 0.0017 | 0.2407 | 0.5 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0027 | 1 | 0.5 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0024 | 0.7743 | 0.5 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0027 | 1 | 0.5 |
Trypanosoma cruzi | p450 reductase, putative | 0.0027 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (functional) | Agonist activity at human mu opioid receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation after 1 hr by HTRF assay | ChEMBL. | 24900459 | |
IC50 (binding) | = 2.76 uM | Inhibition of human recombinant nNOS assessed as conversion of [3H]L-arginine to [3H]L-citrulline preincubated for 15 mins measured after 45 mins by liquid scintillation counting | ChEMBL. | 24900459 |
IC50 (binding) | = 29.5 uM | Inhibition of human recombinant eNOS assessed as conversion of [3H]L-arginine to [3H]L-citrulline preincubated for 15 mins measured after 45 mins by liquid scintillation counting | ChEMBL. | 24900459 |
IC50 (binding) | = 118 uM | Inhibition of human recombinant iNOS assessed as conversion of [3H]L-arginine to [3H]L-citrulline preincubated for 15 mins measured after 45 mins by liquid scintillation counting | ChEMBL. | 24900459 |
Ki (binding) | = 12 nM | Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK-293 cells by scintillation counting | ChEMBL. | 24900459 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.